Cogent Biosciences (COGT) 10-Q 10 Nov 21 2021 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 08, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Entity Registrant Name	Cogent Biosciences, Inc.
Entity Central Index Key	0001622229
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Common Stock, Shares Outstanding		39,851,022
Entity Shell Company	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity File Number	001-38443
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-5308248
Entity Address, Address Line One	200 Cambridge Park Drive
Entity Address, Address Line Two	Suite 2500
Entity Address, City or Town	Cambridge
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02140
City Area Code	(617)
Local Phone Number	945-5576
Title of 12(b) Security	Common Stock, $0.001 Par Value
Trading Symbol	COGT
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 202,888	$ 242,190
Prepaid expenses and other current assets	4,616	2,722
Total current assets	207,504	244,912
Operating lease, right-of-use asset	3,249	4,615
Property and equipment, net	1,341	134
Restricted cash	1,255	1,255
Other assets	2,036
Total assets	215,385	250,916
Current liabilities:
Accounts payable	4,349	732
Accrued expenses and other current liabilities	7,047	4,779
CVR liability (Note 3)	3,060	5,531
Operating lease liability	2,253	2,052
Total current liabilities	16,709	13,094
Operating lease liability, net of current portion	1,438	3,155
Total liabilities	18,147	16,249
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.001 par value; 9,000,000 shares authorized; no shares issued or outstanding
Common stock, $0.001 par value; 150,000,000 shares authorized; 39,851,022 shares and 32,347,905 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively	40	32
Additional paid-in capital	357,859	322,454
Accumulated deficit	(246,061)	(198,700)
Total stockholders’ equity	197,238	234,667
Total liabilities and stockholders’ equity	215,385	250,916
Series A Convertible Preferred Stock [Member]
Stockholders’ equity:
Series A non-voting convertible preferred stock, $0.001 par value; 1,000,000 shares authorized; 103,289 and 132,244 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively	85,400	110,881
Total stockholders’ equity	$ 85,400	$ 110,881

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	9,000,000	9,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, Par value	$ 0.001	$ 0.001
Common stock, Shares authorized	150,000,000	150,000,000
Common stock, Shares issued	39,851,022	32,347,905
Common stock, Shares outstanding	39,851,022	32,347,905
Series A Convertible Preferred Stock [Member]
Non-voting convertible preferred stock, par value	$ 0.001	$ 0.001
Non-voting convertible preferred stock, shares authorized	1,000,000	1,000,000
Non-voting convertible preferred stock, shares issued	103,289	132,244
Non-voting convertible preferred stock, shares outstanding	103,289	132,244

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Collaboration revenue		$ 312		$ 7,871
Operating expenses:
Research and development	$ 14,798	5,003	$ 35,399	19,630
General and administrative	5,021	5,598	14,512	12,074
Acquired in-process research and development		46,910		46,910
Total operating expenses	19,819	57,511	49,911	78,614
Loss from operations	(19,819)	(57,199)	(49,911)	(70,743)
Other income:
Interest income	115	23	360	73
Gain on disposal of long-lived assets		7,463		7,470
Other income	620	239	1,847	239
Change in fair value of CVR liability		(509)	343	(509)
Total other income	735	7,216	2,550	7,273
Net loss and comprehensive loss	(19,084)	(49,983)	(47,361)	(63,470)
Comprehensive loss	$ (19,084)	$ (49,983)	$ (47,361)	$ (63,470)
Net loss per share attributable to common stockholders, basic and diluted	$ (0.48)	$ (5.07)	$ (1.25)	$ (7.56)
Weighted average common shares outstanding, basic and diluted	39,848,943	9,850,530	37,741,526	8,392,741

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	LPC [Member]	KIQ Acquisition [Member]	Series A Non-Voting Convertible Preferred Stock [Member]	Series A Non-Voting Preferred Stock [Member]	Series A Non-Voting Preferred Stock [Member]KIQ Acquisition [Member]	Common Stock [Member]	Common Stock [Member]LPC [Member]	Common Stock [Member]KIQ Acquisition [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member]LPC [Member]	Additional Paid-in Capital [Member]KIQ Acquisition [Member]	Accumulated Deficit [Member]
Beginning Balances at Dec. 31, 2019	$ 31,762						$ 8			$ 155,646			$ (123,892)
Beginning Balances, Shares at Dec. 31, 2019							7,665,763
Issuance of common stock upon exercise of stock options	38									38
Issuance of common stock upon exercise of stock options, Shares							51,823
Issuance of common stock under Employee Stock Purchase Plan	35									35
Issuance of common stock under Employee Stock Purchase Plan, shares							14,252
Issuance of common stock as a commitment fee		$ 262									$ 262
Issuance of common stock as a commitment fee, Shares								181,595
Acquisition and retirement of treasury stock	(808)									(808)
Acquisition and retirement of treasury stock, shares							(207,961)
Stock-based compensation expense	507									507
Net loss	(6,094)												(6,094)
Ending Balances at Mar. 31, 2020	25,702						$ 8			155,680			(129,986)
Ending Balances, Shares at Mar. 31, 2020							7,705,472
Beginning Balances at Dec. 31, 2019	31,762						$ 8			155,646			(123,892)
Beginning Balances, Shares at Dec. 31, 2019							7,665,763
Net loss	(63,470)
Ending Balances at Sep. 30, 2020	(22,174)				$ 138,232		$ 11			165,177			(187,362)
Ending Balances, Shares at Sep. 30, 2020					163,325		10,677,285
Beginning Balances at Mar. 31, 2020	25,702						$ 8			155,680			(129,986)
Beginning Balances, Shares at Mar. 31, 2020							7,705,472
Issuance of common stock upon exercise of stock options	62									62
Issuance of common stock upon exercise of stock options, Shares							85,012
Stock-based compensation expense	870									870
Net loss	(7,393)												(7,393)
Ending Balances at Jun. 30, 2020	19,241						$ 8			156,612			(137,379)
Ending Balances, Shares at Jun. 30, 2020							7,790,484
Issuance of common stock upon exercise of stock options	335									335
Issuance of common stock upon exercise of stock options, Shares							201,017
Issuance of common stock under Employee Stock Purchase Plan	13									13
Issuance of common stock under Employee Stock Purchase Plan, shares							8,293
Issuance of common stock upon RSU vesting, Shares							56,933
Issuance of common stock		$ 10,670						$ 1			$ 10,669
Issuance of common stock, Shares								1,061,583
Issuance of non-voting preferred stock and common stock in connection with the Kiq acquisition			$ 5,488			$ 39,325			$ 2			$ 5,486
Issuance of non-voting preferred stock and common stock in connection with the Kiq acquisition, Shares						44,687			1,558,975
Issuance preferred stock, net of issuance costs					$ 98,907
Issuance of preferred stock, net of issuance costs, Shares					118,638
Dividend payable to common stockholders	(11,450)									(11,450)
Stock-based compensation expense	3,512									3,512
Net loss	(49,983)												(49,983)
Ending Balances at Sep. 30, 2020	(22,174)				$ 138,232		$ 11			165,177			(187,362)
Ending Balances, Shares at Sep. 30, 2020					163,325		10,677,285
Beginning Balances at Dec. 31, 2020	234,667			$ 110,881			$ 32			322,454			(198,700)
Beginning Balances, Shares at Dec. 31, 2020				132,244			32,347,905
Conversion of preferred stock into common stock				$ (16,200)			$ 5			16,195
Conversion of preferred stock into common stock, Shares				(18,409)			4,602,250
Issuance of common stock to settle CVR liability	2,043									2,043
Issuance of common stock to settle CVR liability, Shares							212,429
Issuance of common stock for services	260									260
Issuance of common stock for services, Shares							31,683
Stock-based compensation expense	1,521									1,521
Net loss	(11,728)												(11,728)
Ending Balances at Mar. 31, 2021	226,763			$ 94,681			$ 37			342,473			(210,428)
Ending Balances, Shares at Mar. 31, 2021				113,835			37,194,267
Beginning Balances at Dec. 31, 2020	234,667			$ 110,881			$ 32			322,454			(198,700)
Beginning Balances, Shares at Dec. 31, 2020				132,244			32,347,905
Net loss	(47,361)
Ending Balances at Sep. 30, 2021	197,238			$ 85,400			$ 40			357,859			(246,061)
Ending Balances, Shares at Sep. 30, 2021				103,289			39,851,022
Beginning Balances at Mar. 31, 2021	226,763			$ 94,681			$ 37			342,473			(210,428)
Beginning Balances, Shares at Mar. 31, 2021				113,835			37,194,267
Conversion of preferred stock into common stock				$ (9,281)			$ 3			9,278
Conversion of preferred stock into common stock, Shares				(10,546)			2,636,500
Stock-based compensation expense	2,590									2,590
Net loss	(16,549)												(16,549)
Ending Balances at Jun. 30, 2021	212,804			$ 85,400			$ 40			354,341			(226,977)
Ending Balances, Shares at Jun. 30, 2021				103,289			39,830,767
Issuance of common stock upon exercise of stock options	24									24
Issuance of common stock upon exercise of stock options, Shares							15,758
Issuance of common stock under Employee Stock Purchase Plan	31									31
Issuance of common stock under Employee Stock Purchase Plan, shares							4,497
Stock-based compensation expense	3,463									3,463
Net loss	(19,084)												(19,084)
Ending Balances at Sep. 30, 2021	$ 197,238			$ 85,400			$ 40			$ 357,859			$ (246,061)
Ending Balances, Shares at Sep. 30, 2021				103,289			39,851,022

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Series A Non-Voting Preferred Stock [Member]
Issuance cost	$ 5,493	$ 5,493	$ 5,493

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net loss	$ (47,361)	$ (63,470)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	79	703
Stock-based compensation expense	7,834	5,151
Noncash consideration received from a customer		(808)
Noncash portion of acquired in-process research and development		44,812
Gain on disposal of long-lived assets		(7,470)
Change in fair value of CVR liability	(343)	509
Changes in operating assets and liabilities:
Accounts receivable		2,000
Prepaid expenses and other current assets	(1,894)	(2,769)
Operating lease, right-of-use asset	1,366	239
Other assets	(2,036)	427
Accounts payable	3,617	(2,544)
Accrued expenses and other current liabilities	2,268	(1,596)
Operating lease liability	(1,516)	(353)
Deferred revenue		(1,315)
Net cash used in operating activities	(37,986)	(26,484)
Cash flows from investing activities:
Purchases of property and equipment	(1,286)
Proceeds from sale of property and equipment		320
Proceeds from sale of BOXR Platform assets		8,100
Net cash (used in) provided by investing activities	(1,286)	8,420
Cash flows from financing activities:
Proceeds from issuance of Series A non-voting convertible preferred stock, net of issuance costs of $5,493		98,907
Proceeds from issuance of common stock		10,670
Proceeds from issuance of common stock upon stock option exercises	24	435
Proceeds from issuance of stock from employee stock purchase plan	31	48
Payment to CVR Holders	(85)
Net cash (used in) provided by financing activities	(30)	110,060
Net (decrease) increase in cash, cash equivalents and restricted cash	(39,302)	91,996
Cash, cash equivalents and restricted cash at beginning of period	243,445	38,679
Cash, cash equivalents and restricted cash at end of period	204,143	$ 130,675
Supplemental disclosure of noncash investing and financing information:
Conversion of Series A non-voting convertible preferred stock into common stock	25,481
Issuance of shares in partial settlement of CVR liability	$ 2,043

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Series A Non-Voting Preferred Stock [Member]
Issuance cost	$ 5,493	$ 5,493	$ 5,493

Nature of the Business and Basi

Nature of the Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of the Business and Basis of Presentation	1. Nature of the Business and Basis of Presentation Cogent Biosciences, Inc. (“Cogent” or the “Company”) is a biotechnology company focused on developing precision therapies for genetically defined diseases. Cogent’s approach is to design rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Cogent’s most advanced program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (“SM”), a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (“GIST”), a type of cancer with strong dependence on oncogenic KIT signaling. Bezuclastinib is a highly selective and potent KIT inhibitor with the potential to provide a new treatment option for these patient populations. In addition to bezuclastinib, the Company’s research team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases. The Company was incorporated in March 2014 under the laws of the State of Delaware. On October 2, 2020 the Company filed an amendment to its certificate of incorporation to change its name from Unum Therapeutics Inc. to Cogent Biosciences, Inc. The name change became effective on October 6, 2020. In connection with the name change, the Company’s common stock began trading under the ticker symbol “COGT” and the new CUSIP for the Company’s common stock is 19240Q 201. On July 6, 2020, the Company completed its asset acquisition of Kiq Bio LLC (“Kiq”) (the “Kiq Acquisition”), in accordance with the terms of the Agreement and Plan of Merger (the “Merger Agreement”), signed and closed on July 6, 2020. Under the terms of the Merger Agreement, at the closing of the Merger, the Company issued the securityholders of Kiq 1,558,975 shares of common stock and 44,687 shares of Series A Preferred Stock. On July 9, 2020, the Company completed a Private Investment in Public Equity (“PIPE”) of 118,638 Series A Non-Voting Convertible Preferred Stock to new and existing investors in exchange for gross proceeds of $104.4 million, or net proceeds of $98.9 million, after deducting commissions and offering costs On August 28, 2020, the Company sold its assets, rights and interests relating to its Bolt-on Chimeric Receptor (“ On December 4, 2020, the Company completed an underwritten public offering of 11,794,872 shares of its common stock at a public offering price of $9.75 per share. This included the exercise in full by the underwriters of their 30-day option to purchase up to 1,538,461 additional shares of common stock. The net proceeds from the offering were approximately $107.7 million, after deducting the underwriting discounts and commissions of $6.9 million and offering expenses of $0.4 million. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, the impact of COVID-19, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s drug development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. The accompanying condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has incurred recurring losses since inception, including a net loss of $47.4 million for the nine months ended September 30, 2021. As of September 30, 2021, the Company had an accumulated deficit of $246.1 million. The Company expects to continue to generate operating losses in the foreseeable future. As of the issuance date of the interim condensed consolidated financial statements, the Company expects that its cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from issuance of the condensed consolidated financial statements. The Company expects that it will continue to incur significant expenses in connection with its ongoing business activities. The Company will need to seek additional funding through equity offerings, debt financings, collaborations, licensing arrangements and other marketing and distribution arrangements, partnerships, joint ventures, combinations or divestitures of one or more of its assets or businesses. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborative arrangements or divest its assets. The terms of any financing may adversely affect the holdings or the rights of the Company’s stockholders. Arrangements with collaborators or others may require the Company to relinquish rights to certain of its technologies or product candidates. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate its research and development programs or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. The Company’s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Unaudited Interim Financial Information The consolidated balance sheet at December 31, 2020 was derived from audited financial statements but does not include all disclosures required by GAAP. The accompanying unaudited condensed consolidated financial statements as of September 30, 2021 and for the three and nine months ended September 30, 2021 and 2020 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Mono, Inc. and Kiq Bio LLC. All intercompany accounts and transactions have been eliminated. Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, revenue recognition, the accrual of research and development expenses, the valuation of the CVR liability and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions. Risks and Uncertainties Impact of the COVID-19 Coronavirus The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The impact of the pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will likely continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world. The spread of COVID-19 has caused the Company to modify its business practices, including implementing a work-from-home policy for all employees who are able to perform their duties remotely and restricting all nonessential travel, and it expects to continue to take actions as may be required or recommended by government authorities or as the Company determines are in the best interests of its employees, the patients it serves and other business partners in light of COVID-19. Potential impacts to the Company’s business include temporary closures of its facilities or those of its vendors, disruptions or restrictions on its employees’ ability to travel, disruptions to or delays in ongoing laboratory experiments and operations, the potential diversion of healthcare resources away from the conduct of clinical trials to focus on pandemic concerns, and its ability to raise capital. As of September 30, 2021, there have been no material impacts to the Company. As the impact of COVID-19 continues to unfold, the Company will make continual assessments of the situation, as the extent to which the COVID-19 pandemic may materially impact the Company’s financial condition, liquidity or results of operations in the future is uncertain. Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12 Simplifying the Accounting for Income Taxes Recently Issued Accounting Pronouncements Not Yet Adopted In August 2020, the FASB issued ASU 2020-06 Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)

Fair Value of Financial Assets

Fair Value of Financial Assets and Liabilities	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value of Financial Assets and Liabilities	3. Fair Value of Financial Assets and Liabilities The following tables present information about the Company’s assets that are measured at fair value on a recurring basis (in thousands) Fair Value Measurements at September 30, 2021 Using: Level 1 Level 2 Level 3 Total Liabilities: CVR Liability $ — $ — $ 3,060 $ 3,060 Total Liabilities $ — $ — $ 3,060 $ 3,060 Fair Value Measurements at December 31, 2020 Using: Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market funds $ — $ 486 $ — $ 486 Total Assets $ — $ 486 $ — $ 486 Liabilities: CVR Liability $ — $ — $ 5,531 $ 5,531 Total Liabilities $ — $ — $ 5,531 $ 5,531 Money market funds were valued by the Company using quoted prices in active markets for similar securities, which represent a Level 2 measurement within the fair value hierarchy. On July 6, 2020, the Company issued a non-transferrable CVR, which was distributed to stockholders of record as of the close of business on July 6, 2020, and prior to the issuance of any shares to acquire Kiq or sold to the PIPE investors. Holders of the CVR are entitled to receive certain stock and/or cash payments from proceeds received by the Company, if any, related to the disposition of its legacy cell therapy assets for a period of three years from July 2020. On August 28, 2020, the Company sold the BOXR Platform and subsequently sold additional fixed assets, triggering the CVR payment and, per the terms of the CVR agreement, the payment will be made in shares or cash, depending on the timing of cash receipt. The Company classifies the CVR as a liability on its condensed consolidated balance sheet. The fair value of the CVR liability was determined using the probability weighted discounted cash flow method to estimate future cash flows associated with the sale of the legacy cell therapy assets, including the BOXR platform, ACTR platform and other fixed assets based on assumptions at the date of the CVR issuance and are recognized as a compon ent of Other income (expense) in the condensed consolidated statement of operations and comprehensive loss for the three and nine months ended September 30, 2021 . The liability was valued based on significant inputs not observable in the market, which represents a Level 3 measurement wi thin the fair value hierarchy. In November 2020, the Company issued 707,938 CVR shares of common stock in partial settlement of the CVR liability. In February 2021, the Company issued an additional 212,429 shares of common stock and paid $ 0.1 million in partial settlement of the CVR. Any settlement of the remaining CVR liability will be a cash settlement. The following table sets forth a summary of the changes in the fair value of the Company’s CVR liability (in thousands) For the Nine Months Ended September 30, 2021 Beginning balance $ 5,531 Fair value at CVR issuance — Change in fair value (343 ) CVR settlement (2,128 ) Ending balance $ 3,060 During the three and nine months ended September 30, 2021 and 2020, there were no transfers between Level 1, Level 2 and Level 3

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2021
Payables And Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	4. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following (in thousands) September 30, 2021 December 31, 2020 Accrued employee compensation and benefits $ 2,054 $ 1,443 Accrued external research and development expense 2,025 2,191 Accrued external manufacturing costs 1,335 161 Accrued professional and consulting services 1,408 671 Other 225 313 $ 7,047 $ 4,779

Preferred Stock, Series A Non-V

Preferred Stock, Series A Non-Voting Convertible Preferred Stock and Common Stock	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Preferred Stock, Series A Non-Voting Convertible Preferred Stock and Common Stock	5. Preferred Stock, Series A Non-Voting Convertible Preferred Stock and Common Stock The Company’s authorized capital stock consists of 150,000,000 shares of common stock, par value $0.001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share, 1,000,000 of which are designated as Series A Preferred Stock and 9,000,000 of which shares of preferred stock are undesignated. Series A Non-Voting Convertible Preferred Stock On July 6, 2020, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock (“Series A Preferred Stock”) with the Secretary of State of the State of Delaware (the “Certificate of Designation”) in connection with the Merger and the PIPE. The Certificate of Designation provides for the issuance of shares of Series A Preferred Stock, par value $0.001 per share. Holders of Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock equal, on an as-if-converted-to-common-stock basis, and in the same form as dividends actually paid on shares of the common stock. Except as otherwise required by law, the Series A Preferred Stock does not have voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock, (b) alter or amend the Certificate of Designation, (c) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series A Preferred Stock, (d) increase the number of authorized shares of Series A Preferred Stock, (e) prior to the stockholder approval of the Conversion Proposal or at any time while at least 40% of the originally issued Series A Preferred Stock remains issued and outstanding, consummate a Fundamental Transaction (as defined in the Certificate of Designation) or (f) enter into any agreement with respect to any of the foregoing. The Series A Preferred Stock does not have a preference upon any liquidation, dissolution or winding-up of the Company. Each share of Series A Preferred Stock is convertible at any time at the option of the holder thereof, into 250 shares of common stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. Cumulatively, through September 30, 2021, 60,036 shares of Series A Preferred Stock, or 36.8% of the issued Series A Preferred Stock, have been converted into 15,009,000 shares of common stock. No other classes of preferred stock have been designated and no other preferred shares have been issued or are outstanding as of September 30, 2021. Common Stock Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are not entitled to receive dividends, unless declared by the board of directors. In the event of the Company’s liquidation, dissolution or winding up, holders of the Company’s common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock. The shares to be issued by us in this offering will be, when issued and paid for, validly issued, fully paid and non-assessable. On September 22, 2020, the Company filed a registration statement on Form S-3 for the registration of (i) 1,558,975 shares of common stock issued in the acquisition of Kiq, (ii) 11,171,750 shares of common stock issuable upon the conversion of 44,687 shares of the Series A Preferred Stock issued in the acquisition of Kiq and (iii) 29,659,500 shares of common stock issuable upon the conversion of 118,638 shares of the Series A Preferred Stock issued in the PIPE, for a total of 42,390,225 shares of common stock. On December 4, 2020, the Company completed an underwritten public offering of 11,794,872 shares of its common stock at a public offering price of $9.75 per share. This included the exercise in full by the underwriters of their 30-day option to purchase up to 1,538,461 additional shares of common stock. The net proceeds from the offering were approximately $107.7 million, after deducting the underwriting discounts and commissions and offering expenses of $7.3 million. On February 8, 2021, the Company filed a shelf registration statement on Form S-3 with the SEC. The shelf registration statement allows the Company to sell from time-to-time up to $200.0 million of common stock, preferred stock, debt securities, warrants or units comprised of any combination of these securities, for its own account in one or more offerings. The terms of any offering under the shelf registration statement will be established at the time of such offering and will be described in a prospectus supplement filed with the SEC prior to the completion of any such offering. Additionally, on February 8, 2021, pursuant to the Form S-3, the Company entered into a Sales Agreement (the “Sales Agreement”) with SVB Leerink LLC (“SVB Leerink”), pursuant to which the Company may issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to $75.0 million through SVB Leerink as the sales agent. As of September 30, 2021, no shares have been sold under the Sales Agreement.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	6. Stock-Based Compensation 2018 Stock Option and Incentive Plan The Company’s 2018 Stock Option and Incentive Plan, (the “2018 Plan”), which became effective on March 27, 2018, provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights. The number of shares initially reserved for issuance under the 2018 Plan was 700,180. Additionally, the shares of common stock that remained available for issuance under the previously outstanding 2015 Stock Incentive Plan (the “2015 Plan”) became available under the 2018 Plan. The number of shares reserved for the 2018 Plan automatically increases on each January 1 by 4% of the number of shares of the Company’s common stock outstanding on the immediately preceding December 31 or a lesser number of shares determined by the Company’s board of directors. The shares of common stock underlying any awards that are forfeited, canceled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, repurchased or are otherwise terminated by the Company under the 2018 Plan or the 2015 Plan will be added back to the shares of common stock available for issuance under the 2018 Plan. The number of authorized shares reserved for issuance under the 2018 Plan was increased by 1,293,916 shares effective as of January 1, 2021. On June 16, 2021, at the Company’s 2021 annual stockholder meeting, the Company’s stockholders approved the amendment and restatement of the 2018 Stock Plan to increase the number of shares of common stock issuable under the 2018 Plan by 6,000,000 shares. Upon stockholder approval, in accordance with ASC 718- Compensation- Stock Compensation Inducement Plan On October 22, 2020, the board of directors adopted the Cogent Biosciences, Inc. 2020 Inducement Plan (the “Inducement Plan”). The board of directors also adopted a form of non-qualified stock option agreement for use with the Inducement Plan. A total of 3,750,000 shares of common stock have been reserved for issuance under the Inducement Plan, subject to adjustment for stock dividends, stock splits, or other changes in Cogent’s common stock or capital structure. On November 5, 2020, the Company filed a Registration on Form S-8 related to the 3,750,000 shares of its common stock reserved for issuance under the Inducement Plan. The Company has granted 3,021,005 2018 Employee Stock Purchase Plan The Company’s 2018 Employee Stock Purchase Plan (the “ESPP”) became effective on March 28, 2018, at which time a total of 78,500 shares of common stock were reserved for issuance. In addition, the number of shares of common stock that may be issued under the ESPP automatically increases on each January 1 through January 1, 2027, by the least of (i) 125,000 shares of common stock, (ii) 1% of the number of shares of the Company’s common stock outstanding on the immediately preceding December 31 or (iii) such lesser number of shares as determined by the ESPP administrator. The number of authorized shares reserved for issuance under the ESPP was increased by 125,000 shares effective as of January 1, 2021. In July 2021, 4,497 shares were issued to employees under the ESPP. As of September 30, 2021, 336,919 shares remain available for issuance under the ESPP. Stock-Based Compensation The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss (in thousands) Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Research and development expenses $ 1,436 $ 1,876 $ 2,650 $ 2,579 General and administrative expenses 2,027 1,636 5,184 2,572 Total $ 3,463 $ 3,512 $ 7,834 $ 5,151 On July 6, 2020, all then outstanding stock options became fully vested in connection with the Kiq Acquisition, resulting in acceleration of stock compensation expense of $2.9 million, which was recognized in the year ended December 31, 2020. As of September 30, 2021, total unrecognized compensation cost related to the unvested stock-based options was $42.6 million, which is expected to be recognized over a weighted average period of 3.27 years.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	7. Commitments and Contingencies Operating Leases Corporate Headquarters- Cambridge, MA The Company leases office and laboratory space in Cambridge, MA On August 28, 2020, the Company amended the lease (the “Cambridge Lease Amendment”) resulting in increased annual rent payments. No other terms of the Cambridge Lease were changed. The Company determined that the lease modification did not grant an additional right of use and concluded that the modification was not a separate new lease, but rather that it should reassess and remeasure the right-of-use asset and lease liability on the effective date of the modification. The Company increased the right-of-use asset and operating lease liabilities by $0.9 million, respectively. Concurrent with the Cambridge Lease Amendment and the BOXR sale, the Company entered into a sublease (the “Cambridge Sublease Agreement”) for a significant portion of the leased premises for the remaining term of the lease. Under the terms of the Cambridge Sublease Agreement, the sublessee leased approximately 70% of the facility and is responsible for the corresponding percentage of operating lease costs and variable lease costs. Variable lease costs include common area maintenance and other operating charges. The elements of the lease expense, net of sublease income, were as follows (in thousands): Nine Months Ended September 30, 2021 Lease cost Operating lease cost $ 1,812 Variable lease cost (1) 616 Sublease Income (1,848 ) Total lease cost $ 580 Other information Cash paid for amounts included in the measurement of lease liabilities $ 2,428 Remaining lease term 1.58 Discount rate 9.50 % (1) The variable lease costs for the nine months ended September 30, 2021 include common area maintenance and other operating charges. Future minimum lease payments under the operating lease as of September 30, 2021 are as follows (in thousands): Year Ending December 31, 2021 816 2022 2,497 2023 841 Total future minimum lease payments 4,154 Less: imputed interest 463 Total operating lease liability $ 3,691 Included in the consolidated balance sheet: Current operating lease liability $ 2,253 Operating lease liability, net of current portion 1,438 Total operating lease liability $ 3,691 Under the terms of the Cambridge Lease, the Company issued a $1.3 million letter of credit to the landlord as collateral for the leased facility. The underlying cash collateralizing this letter of credit has been classified as non-current restricted cash in the accompanying condensed consolidated balance sheets. This is a refundable deposit and not a lease payment. Under the terms of the Cambridge Sublease Agreement, the sublessee obtained a letter of credit for $1.3 million for the benefit of the Company. This has been excluded from the undiscounted cash flows above. Boulder Lease On July 6, 2021, the Company entered into a lease agreement (the “Boulder Lease”) pursuant to which the Company leases approximately 38,075 square feet at 4840 Pearl East Circle, Boulder, Colorado, which will include office and laboratory space. The landlord will contribute an aggregate of approximately $6.9 million toward the cost of landlord assets (the “Improvements”), as well as an additional amount of up to approximately $2.3 million in the form of a tenant improvement loan at an annual interest rate of 6%. Any monies borrowed under the tenant improvement loan are required to be repaid over the Boulder Lease term. Boulder Lease payments will begin upon the earlier of (i) substantial completion of the Improvements or (ii) May 1, 2022. The Company will be entitled to 14 months of free rent, followed by an initial Boulder Lease term of 12 years. The Company also has the option to extend the Boulder Lease for three successive five-year terms. Upon the commencement of its obligation to pay rent, the Company will pay the landlord base rent at an initial rate of $40.00 per square foot per year. Rent will be payable in equal monthly installments and subject to 2.5% annual increases over the term. Additionally, the Company is responsible for reimbursing the landlord for its share of the building’s property taxes and operating expenses. In connection with the Boulder Lease, the Company provided a cash security deposit to the landlord in an amount of $0.7 million which is recorded in Other Assets in the condensed consolidated balance sheet as of September 30, 2021. The Company has determined this is a lease under ASC 842. The Company gained access to the leased space on August 14, 2021, to commence construction of the Improvements. As of September 30, 2021, the Company has determined that it does not have control of the space, as defined in ASC 842, during the construction period and as such, the accounting lease commencement date has not occurred for the Boulder Lease as of September 30, 2021. Therefore, the Company will not record a right-of-use asset or lease liability for the Boulder Lease until the accounting lease commencement date which is expected to be in 2022. The Company has determined the cost of Improvements during the construction period are lessor assets and considered a prepayment of lease under ASC 842. The Company has paid $0.9 million towards the construction of lessor assets, which is included in Other Assets in the condensed consolidated balance sheet as of September 30, 2021. License Agreements Plexxikon License Agreement In July 2020, the Company obtained an exclusive, sublicensable, worldwide license (the “License Agreement”) to certain patents and other intellectual property rights to research, develop and commercialize bezuclastinib and CGT0206. Under the terms of the License Agreement, the Company is required to pay Plexxikon Inc. (“Plexxikon”) aggregate payments of up to $7.5 million upon the satisfaction of certain clinical milestones and up to $25.0 million upon the satisfaction of certain regulatory milestones. The Company is also required to pay Plexxikon tiered royalties ranging from a low-single digit percentage to a high-single digit percentage on annual net sales of products. These royalty obligations last on a product-by-product basis and country-by-country basis until the latest of (i) the date on which there is no validate claim of a licensed Plexxikon patent covering a subject product in such country or (ii) the 10 th The license agreement will expire on a country-by-country and licensed product-by-licensed product basis until the later of the last to expire of the patents covering such licensed products or services or the 10-year anniversary of the date of first commercial sale of the licensed product in such country. The Company may terminate the license agreement within 30 days after written notice in the event of a material breach. The Company may also terminate the agreement upon written notice in the event of the Company’s bankruptcy, liquidation or insolvency. In addition, the Company has the right to terminate this agreement in its entirety at will upon 90 days’ advance written notice to Plexxikon. Indemnification Agreements In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any claims under indemnification arrangements that will have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its condensed consolidated financial statements as of September 30, 2021 or its consolidated financial statements as of December 31, 2020. Legal Proceedings The Company is not currently party to any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Net Loss Per Share	8. Net Loss Per Share Basic and diluted net loss per common share was calculated as follows (in thousands, except share and per share amounts) Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Numerator: Net loss $ (19,084 ) $ (49,983 ) $ (47,361 ) $ (63,470 ) Net loss attributable to common stockholders $ (19,084 ) $ (49,983 ) $ (47,361 ) $ (63,470 ) Denominator: Weighted average common shares outstanding, basic and diluted 39,848,943 9,850,530 37,741,526 8,392,741 Net loss per common share, basic and diluted $ (0.48 ) $ (5.07 ) $ (1.25 ) $ (7.56 ) The Company’s potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be anti-dilutive and would result in a reduction to net loss per share. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated above because including them would have had an anti-dilutive effect: September 30, 2021 2020 Stock options to purchase common stock 8,156,538 668,360 Series A Preferred Stock 25,822,250 40,831,250 33,978,788 41,499,610

Retirement Plan

Retirement Plan	9 Months Ended
	Sep. 30, 2021
Compensation And Retirement Disclosure [Abstract]
Retirement Plan	9. Retirement Plan The Company has a defined-contribution plan under Section 401(k) of the Internal Revenue Code (the “401(k) Plan”). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. The 401(k) Plan allows for discretionary matching contributions of 100% of the first 4% of elective contributions, which vest immediately. Contributions under the plan were approximately $0.1 million for the three months ended September 30, 2021 and $0.3 million for the nine months ended September 30, 2021. The Company did not make any matching contributions during the three and nine months ended September 30, 2020.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
Subsequent Events

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Unaudited Interim Financial Information	Unaudited Interim Financial Information The consolidated balance sheet at December 31, 2020 was derived from audited financial statements but does not include all disclosures required by GAAP. The accompanying unaudited condensed consolidated financial statements as of September 30, 2021 and for the three and nine months ended September 30, 2021 and 2020 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K
Principles of Consolidation	Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Mono, Inc. and Kiq Bio LLC. All intercompany accounts and transactions have been eliminated.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, revenue recognition, the accrual of research and development expenses, the valuation of the CVR liability and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions.
Risks and Uncertainties	Risks and Uncertainties Impact of the COVID-19 Coronavirus The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The impact of the pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will likely continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world. The spread of COVID-19 has caused the Company to modify its business practices, including implementing a work-from-home policy for all employees who are able to perform their duties remotely and restricting all nonessential travel, and it expects to continue to take actions as may be required or recommended by government authorities or as the Company determines are in the best interests of its employees, the patients it serves and other business partners in light of COVID-19. Potential impacts to the Company’s business include temporary closures of its facilities or those of its vendors, disruptions or restrictions on its employees’ ability to travel, disruptions to or delays in ongoing laboratory experiments and operations, the potential diversion of healthcare resources away from the conduct of clinical trials to focus on pandemic concerns, and its ability to raise capital. As of September 30, 2021, there have been no material impacts to the Company. As the impact of COVID-19 continues to unfold, the Company will make continual assessments of the situation, as the extent to which the COVID-19 pandemic may materially impact the Company’s financial condition, liquidity or results of operations in the future is uncertain.
Recently Adopted and Issued Accounting Pronouncements Not Yet Adopted	Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12 Simplifying the Accounting for Income Taxes Recently Issued Accounting Pronouncements Not Yet Adopted In August 2020, the FASB issued ASU 2020-06 Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)

Fair Value of Financial Asset_2

Fair Value of Financial Assets and Liabilities (Tables)	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of Assets Measured at Fair Value on Recurring Basis	The following tables present information about the Company’s assets that are measured at fair value on a recurring basis (in thousands) Fair Value Measurements at September 30, 2021 Using: Level 1 Level 2 Level 3 Total Liabilities: CVR Liability $ — $ — $ 3,060 $ 3,060 Total Liabilities $ — $ — $ 3,060 $ 3,060 Fair Value Measurements at December 31, 2020 Using: Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market funds $ — $ 486 $ — $ 486 Total Assets $ — $ 486 $ — $ 486 Liabilities: CVR Liability $ — $ — $ 5,531 $ 5,531 Total Liabilities $ — $ — $ 5,531 $ 5,531
Summary of Changes in the Fair Value of Company's CVR Liability	The following table sets forth a summary of the changes in the fair value of the Company’s CVR liability (in thousands) For the Nine Months Ended September 30, 2021 Beginning balance $ 5,531 Fair value at CVR issuance — Change in fair value (343 ) CVR settlement (2,128 ) Ending balance $ 3,060

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2021
Payables And Accruals [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consisted of the following (in thousands) September 30, 2021 December 31, 2020 Accrued employee compensation and benefits $ 2,054 $ 1,443 Accrued external research and development expense 2,025 2,191 Accrued external manufacturing costs 1,335 161 Accrued professional and consulting services 1,408 671 Other 225 313 $ 7,047 $ 4,779

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Stock Based Compensation Expense	The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss (in thousands) Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Research and development expenses $ 1,436 $ 1,876 $ 2,650 $ 2,579 General and administrative expenses 2,027 1,636 5,184 2,572 Total $ 3,463 $ 3,512 $ 7,834 $ 5,151

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2021
Commitments And Contingencies Disclosure [Abstract]
Summary of Elements of Lease Expense Net of Sublease Income	The elements of the lease expense, net of sublease income, were as follows (in thousands): Nine Months Ended September 30, 2021 Lease cost Operating lease cost $ 1,812 Variable lease cost (1) 616 Sublease Income (1,848 ) Total lease cost $ 580 Other information Cash paid for amounts included in the measurement of lease liabilities $ 2,428 Remaining lease term 1.58 Discount rate 9.50 % (1) The variable lease costs for the nine months ended September 30, 2021 include common area maintenance and other operating charges.
Summary of Future Minimum Payments under Operating Lease	Future minimum lease payments under the operating lease as of September 30, 2021 are as follows (in thousands): Year Ending December 31, 2021 816 2022 2,497 2023 841 Total future minimum lease payments 4,154 Less: imputed interest 463 Total operating lease liability $ 3,691 Included in the consolidated balance sheet: Current operating lease liability $ 2,253 Operating lease liability, net of current portion 1,438 Total operating lease liability $ 3,691

Net Loss per Share (Tables)

Net Loss per Share (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Schedule of Earnings Per Share Basic and Diluted	Basic and diluted net loss per common share was calculated as follows (in thousands, except share and per share amounts) Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Numerator: Net loss $ (19,084 ) $ (49,983 ) $ (47,361 ) $ (63,470 ) Net loss attributable to common stockholders $ (19,084 ) $ (49,983 ) $ (47,361 ) $ (63,470 ) Denominator: Weighted average common shares outstanding, basic and diluted 39,848,943 9,850,530 37,741,526 8,392,741 Net loss per common share, basic and diluted $ (0.48 ) $ (5.07 ) $ (1.25 ) $ (7.56 )
Summary of Potential Dilutive Securities	The Company’s potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be anti-dilutive and would result in a reduction to net loss per share. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated above because including them would have had an anti-dilutive effect: September 30, 2021 2020 Stock options to purchase common stock 8,156,538 668,360 Series A Preferred Stock 25,822,250 40,831,250 33,978,788 41,499,610

Nature of the Business and Ba_2

Nature of the Business and Basis of Presentation - Additional Information (Detail) - USD ($)

Dec. 04, 2020

Sep. 22, 2020

Jul. 09, 2020

Jul. 06, 2020

Sep. 30, 2021

Jun. 30, 2021

Mar. 31, 2021

Sep. 30, 2020

Jun. 30, 2020

Mar. 31, 2020

Sep. 30, 2021

Sep. 30, 2020

Dec. 31, 2020

Aug. 28, 2020

Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]

Proceeds from issuance of common stock

$ 10,670,000

Net loss

$ (19,084,000)

$ (16,549,000)

$ (11,728,000)

$ (49,983,000)

$ (7,393,000)

$ (6,094,000)

$ (47,361,000)

$ (63,470,000)

Accumulated deficit

$ (246,061,000)

$ (246,061,000)

$ (198,700,000)

BOXR Platform [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | SOTIO [Member]

Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]

Disposal group, not discontinued operation, upfront payment

$ 8,100,000

BOXR Platform [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | SOTIO [Member] | Maximum [Member]

Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]

Disposal group, not discontinued operation, cash consideration

11,500,000

Disposal group, not discontinued operation, potential milestone payments upon achievement of specified claims issuance

$ 3,400,000

Underwritten Public Offering [Member]

Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]

Shares of common stock issued and sold

11,794,872

Public offering price, per share

$ 9.75

Underwriters exercise period option

30 days

Issuance of common stock upon exercise of stock options, Shares

1,538,461

Proceeds from issuance of common stock

$ 107,700,000

Underwriting discounts and commissions expenses

6,900,000

Offering expenses

$ 400,000

Common Stock [Member]

Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]

Issuance of common stock upon exercise of stock options, Shares

15,758

201,017

85,012

51,823

Kiq LLC [Member] | Common Stock [Member]

Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]

Shares of common stock issued and sold

1,558,975

1,558,975

Kiq LLC [Member] | Series A Preferred Stock [Member]

Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]

Shares of common stock issued and sold

44,687

Gross proceeds from private placement

$ 104,400,000

Net proceeds from private placement after deducting commissions and offering costs

$ 98,900,000

Kiq LLC [Member] | Series A Preferred Stock [Member] | Private Placement [Member]

Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]

Shares of common stock issued and sold

118,638

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail) - Accounting Standards Update 2019-12 [Member]	Sep. 30, 2021
Summary of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	true
Change in accounting principle, accounting standards update, adoption date	Jan. 1, 2021
Change in accounting principle, accounting standards update, immaterial effect [true false]	true

Fair Value of Financial Asset_3

Fair Value of Financial Assets and Liabilities - Schedule of Assets Measured at Fair Value on Recurring Basis (Detail) - Recurring Basis [Member] - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Assets:
Total Assets		$ 486
Liabilities:
CVR Liability	$ 3,060	5,531
Total Liabilities	3,060	5,531
Level 2 [Member]
Assets:
Total Assets		486
Level 3 [Member]
Liabilities:
CVR Liability	3,060	5,531
Total Liabilities	$ 3,060	5,531
Money Market Funds [Member]
Assets:
Cash equivalents		486
Money Market Funds [Member] | Level 2 [Member]
Assets:
Cash equivalents		$ 486

Fair Value of Financial Asset_4

Fair Value of Financial Assets and Liabilities - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		9 Months Ended
	Feb. 28, 2021	Nov. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Jul. 06, 2020
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Closing price of stock					$ 8.80
Fair value asset, transfers between Level 1, Level 2 and Level 3, amount			$ 0	$ 0
CVR Liability [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
CVR liability, term					3 years
Issuance of common stock, Shares	212,429	707,938
Partial settlement	$ 100		$ 2,128

Fair Value of Financial Asset_5

Fair Value of Financial Assets and Liabilities - Summary of Changes in the Fair Value of Company's CVR Liability (Detail) - CVR Liability [Member] - USD ($) $ in Thousands	1 Months Ended	9 Months Ended
	Feb. 28, 2021	Sep. 30, 2021
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balance		$ 5,531
Change in fair value		(343)
CVR settlement	$ (100)	(2,128)
Ending balance		$ 3,060

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Payables And Accruals [Abstract]
Accrued employee compensation and benefits	$ 2,054	$ 1,443
Accrued external research and development expense	2,025	2,191
Accrued external manufacturing costs	1,335	161
Accrued professional and consulting services	1,408	671
Other	225	313
Total	$ 7,047	$ 4,779

Preferred Stock, Series A Non_2

Preferred Stock, Series A Non-Voting Convertible Preferred Stock and Common Stock - Additional Information (Detail) - USD ($)	Feb. 08, 2021	Dec. 04, 2020	Sep. 22, 2020	Jul. 09, 2020	Jul. 06, 2020	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2021	Dec. 31, 2020
Class Of Stock [Line Items]
Common stock, Shares authorized								150,000,000	150,000,000
Common stock, Par value								$ 0.001	$ 0.001
Preferred stock including temporary equity shares authorized								10,000,000
Preferred stock, par value								$ 0.001	$ 0.001
Preferred stock, shares authorized								9,000,000	9,000,000
Preferred stock, shares issued								0	0
Preferred stock, shares outstanding								0	0
Common stock, Shares issued			42,390,225					39,851,022	32,347,905
SVB Leerink LLC [Member]
Class Of Stock [Line Items]
Shares of common stock issued and sold								0
Private Placement [Member]
Class Of Stock [Line Items]
Common stock issuable upon the conversion of preferred stock			29,659,500
Underwritten Public Offering [Member]
Class Of Stock [Line Items]
Shares of common stock issued and sold		11,794,872
Public offering price, per share		$ 9.75
Net proceeds from public offering		$ 107,700,000
Underwriting discounts and commissions and offering expenses		$ 7,300
Kiq LLC [Member]
Class Of Stock [Line Items]
Common stock issuable upon the conversion of preferred stock			11,171,750
Maximum [Member]
Class Of Stock [Line Items]
Proceeds from issuance of equity and debt financing	$ 200,000,000
Maximum [Member] | SVB Leerink LLC [Member]
Class Of Stock [Line Items]
Stock offering cost	$ 75,000,000
Maximum [Member] | Underwritten Public Offering [Member]
Class Of Stock [Line Items]
Shares of common stock issued and sold		1,538,461
Common Stock [Member]
Class Of Stock [Line Items]
Conversion of preferred stock into common stock, Shares						2,636,500	4,602,250
Common stock voting right								Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders.
Common Stock [Member] | Kiq LLC [Member]
Class Of Stock [Line Items]
Shares of common stock issued and sold			1,558,975		1,558,975
Series A Preferred Stock [Member]
Class Of Stock [Line Items]
Non-voting convertible preferred stock, shares authorized								1,000,000
Non-voting convertible preferred stock, par value								$ 0.001
Minimum percentage of originally issued shares remain issued and outstanding								40.00%
Convertible preferred stock, common stock issuable upon conversion								250
Conversion of preferred stock into common stock, Shares								60,036
Percentage of preferred stock issued								36.80%
Series A Preferred Stock [Member] | Private Placement [Member]
Class Of Stock [Line Items]
Preferred stock shares issued upon conversion			118,638
Series A Preferred Stock [Member] | Kiq LLC [Member]
Class Of Stock [Line Items]
Shares of common stock issued and sold					44,687
Preferred stock shares issued upon conversion			44,687
Series A Preferred Stock [Member] | Kiq LLC [Member] | Private Placement [Member]
Class Of Stock [Line Items]
Shares of common stock issued and sold				118,638
Series A Preferred Stock [Member] | Minimum [Member]
Class Of Stock [Line Items]
Beneficial ownership limitation percentage for conversion of common stock issued and outstanding								4.90%
Series A Preferred Stock [Member] | Maximum [Member]
Class Of Stock [Line Items]
Beneficial ownership limitation percentage for conversion of common stock issued and outstanding								19.90%
Series A Preferred Stock [Member] | Common Stock [Member]
Class Of Stock [Line Items]
Cumulative amount of shares conversion								15,009,000

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ in Millions	Jun. 16, 2021	Jan. 01, 2021	Mar. 28, 2018	Mar. 27, 2018	Sep. 30, 2021	Sep. 30, 2021	Dec. 31, 2020	Jul. 31, 2021	Nov. 05, 2020	Oct. 22, 2020	Sep. 22, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares issued					39,851,022	39,851,022	32,347,905				42,390,225
2020 Inducement Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for issuance					728,995	728,995
Shares reserved for future issuance									3,750,000	3,750,000
Options granted					1,160,400	3,021,005
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost					$ 42.6	$ 42.6
Unrecognized compensation expenses, recognition period					3 years 3 months 7 days
Stock Option [Member] | Kiq LLC [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense due to accelerated vesting of stock options							$ 2.9
2018 Stock Option and Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of increases in authorized shares				700,180
Percentage applied to the outstanding shares as annual increase in the number of shares authorized for issuance				4.00%
Increased in authorized shares reserved for issuance	6,000,000	1,293,916
Shares available for issuance					3,716,296	3,716,296
2018 Stock Option and Incentive Plan [Member] | Employees and Non-employee Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option grants					3,402,768
2018 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increased in authorized shares reserved for issuance		125,000
Shares available for issuance					336,919	336,919
Shares reserved for future issuance			78,500
2018 Employee Stock Purchase Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of increases in authorized shares			125,000
Percentage of shares of common stock available for issuance			1.00%
2018 Employee Stock Purchase Plan [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares issued								4,497

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Stock Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation expense	$ 3,463	$ 3,512	$ 7,834	$ 5,151
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation expense	1,436	1,876	2,650	2,579
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation expense	$ 2,027	$ 1,636	$ 5,184	$ 2,572

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Thousands	Jul. 06, 2021USD ($)ft²$ / ft²	Jul. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Dec. 31, 2020USD ($)	Aug. 28, 2020USD ($)
Commitments And Contingencies Disclosure [Line Items]
Lease expiration month and year			2023-04
Lessee, operating lease, existence of option to extend			true
Operating Lease option to extend			the Company’s option to extend for an additional five-year term.
Right-of-use asset			$ 3,249	$ 4,615	$ 900
Operating lease liabilities			$ 3,691		$ 900
Plexxikon License Agreement [Member]
Commitments And Contingencies Disclosure [Line Items]
License agreement expiration terms			The license agreement will expire on a country-by-country and licensed product-by-licensed product basis until the later of the last to expire of the patents covering such licensed products or services or the 10-year anniversary of the date of first commercial sale of the licensed product in such country. The Company may terminate the license agreement within 30 days after written notice in the event of a material breach. The Company may also terminate the agreement upon written notice in the event of the Company’s bankruptcy, liquidation or insolvency. In addition, the Company has the right to terminate this agreement in its entirety at will upon 90 days’ advance written notice to Plexxikon.
Maximum [Member] | Plexxikon License Agreement [Member]
Commitments And Contingencies Disclosure [Line Items]
Aggregate payments received upon satisfaction of clinical milestones		$ 7,500
Aggregate payments received		$ 25,000
Office and Laboratory Space [Member] | The Boulder Lease [Member]
Commitments And Contingencies Disclosure [Line Items]
Lessee, operating lease, existence of option to extend	true
Operating Lease option to extend	The Company also has the option to extend the Boulder Lease for three successive five-year terms.
Lease deposit			$ 700
Area of lease agreement | ft²	38,075
Aggregate cost of Improvements to landlord assets	$ 6,900
Tenant improvement	$ 2,300
Tenant improvement loan annual interest rate	6.00%
Lease description	Boulder Lease payments will begin upon the earlier of (i) substantial completion of the Improvements or (ii) May 1, 2022. The Company will be entitled to 14 months of free rent, followed by an initial Boulder Lease term of 12 years.
Lease, term of contract	12 years
Base rent initial rate per square foot | $ / ft²	40
Rent annual increases percentage	2.50%
Non-current restricted cash [Member] | Letter of Credit [Member] | Collateral [Member]
Commitments And Contingencies Disclosure [Line Items]
Lease deposit			1,300
Other Assets [Member] | Office and Laboratory Space [Member] | The Boulder Lease [Member]
Commitments And Contingencies Disclosure [Line Items]
Payments for construction of lessor assets			$ 900
SOTIO [Member]
Commitments And Contingencies Disclosure [Line Items]
Percentage of sublease facility			70.00%
SOTIO [Member] | Non-current restricted cash [Member] | Letter of Credit [Member] | Collateral [Member]
Commitments And Contingencies Disclosure [Line Items]
Lease deposit			$ 1,300

Commitments and Contingencies_2

Commitments and Contingencies - Summary of Elements of Lease Expense Net of Sublease Income (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Lease cost
Operating lease cost	$ 1,812
Variable lease cost (1)	616	[1]
Sublease Income	(1,848)
Total lease cost	580
Other information
Cash paid for amounts included in the measurement of lease liabilities	$ 2,428
Remaining lease term	1 year 6 months 29 days
Discount rate	9.50%
[1]	The variable lease costs for the nine months ended September 30, 2021 include common area maintenance and other operating charges.

Commitments and Contingencies_3

Commitments and Contingencies - Summary of Future Minimum Payments under Operating Lease (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020	Aug. 28, 2020
Leases [Abstract]
2021	$ 816
2022	2,497
2023	841
Total future minimum lease payments	4,154
Less: imputed interest	463
Operating lease liabilities	3,691		$ 900
Operating lease liability	2,253	$ 2,052
Operating lease liability, net of current portion	1,438	$ 3,155
Total operating lease liability	$ 3,691		$ 900

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Earnings Per Share Basic and Diluted (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020
Earnings Per Share [Abstract]
Net loss	$ (19,084)	$ (16,549)	$ (11,728)	$ (49,983)	$ (7,393)	$ (6,094)	$ (47,361)	$ (63,470)
Net loss attributable to common stockholders	$ (19,084)			$ (49,983)			$ (47,361)	$ (63,470)
Weighted average common shares outstanding, basic and diluted	39,848,943			9,850,530			37,741,526	8,392,741
Net loss per share attributable to common stockholders, basic and diluted	$ (0.48)			$ (5.07)			$ (1.25)	$ (7.56)

Net Loss Per Share - Summary of

Net Loss Per Share - Summary of Potential Dilutive Securities (Detail) - shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential dilutive securities excluded from computation of diluted net loss per common share	33,978,788	41,499,610
Stock Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential dilutive securities excluded from computation of diluted net loss per common share	8,156,538	668,360
Series A Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential dilutive securities excluded from computation of diluted net loss per common share	25,822,250	40,831,250

Retirement Plan - Additional In

Retirement Plan - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Defined Contribution Plan Disclosure [Line Items]
Defined contribution plan, employer matching contribution percentage of match			100.00%
Defined contribution plan, matching amount	$ 100,000	$ 0	$ 300,000	$ 0
Maximum [Member]
Defined Contribution Plan Disclosure [Line Items]
Defined contribution plan, employer matching contribution percent			4.00%